GIP/GLP1 co-agonist compounds
AssigneeEli Lilly and Company
InventorsJorge Alsina-Fernandez, Robert Andrew Brown, Mohamed ElSayed Hamed ElSayed, Hongchang Qu, Huyen Thanh Tran, Aktham Aburub, Phenil Jayantilal Patel
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
Claims20
A compound, or pharmaceutically acceptable salt thereof, wherein the compound is (D-Tyr)-Aib-EGTFTSDYSI-αMeL-LDKK((2-(2-(2-Amino-ethoxy)-ethoxyl-acetyl)2-(γGlu)-CO—(CH2)16—CO2H)AQ-Aib-EFIE-αMeY-LIAGGPSSGAPPPS-NH2 (SEQ ID NO:307).
Dependencies are inferred from the claim text.